Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Sales (2018 - 2025)

Historic Return on Sales for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 4.65%.

  • Aclaris Therapeutics' Return on Sales fell 27000.0% to 4.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.22%, marking a year-over-year decrease of 78100.0%. This contributed to the annual value of 7.05% for FY2024, which is 42200.0% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Return on Sales of 4.65% as of Q3 2025, which was down 27000.0% from 9.22% recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Return on Sales peaked at 0.11% during Q4 2023, and registered a low of 17.02% during Q2 2023.
  • Moreover, its 5-year median value for Return on Sales was 9.87% (2021), whereas its average is 8.71%.
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -158700bps in 2021, then skyrocketed by 130500bps in 2024.
  • Aclaris Therapeutics' Return on Sales (Quarter) stood at 15.25% in 2021, then surged by 75bps to 3.75% in 2022, then soared by 97bps to 0.11% in 2023, then crashed by -9917bps to 10.59% in 2024, then skyrocketed by 56bps to 4.65% in 2025.
  • Its Return on Sales was 4.65% in Q3 2025, compared to 9.22% in Q2 2025 and 10.94% in Q1 2025.